MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

MDT

89.64

-0.03%↓

VEEV

281.99

+1.94%↑

A

113.98

-2.16%↓

WBA

11.48

-0.26%↓

HQY

97.59

-2.48%↓

Search

Allogene Therapeutics Inc

Затворен

СекторЗдравеопазване

1.25 1.63

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.24

Максимум

1.31

Ключови измерители

By Trading Economics

Приходи

206K

-60M

Марж на печалбата

272,450

Служители

226

EBITDA

-302K

-56M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+593.6% upside

Дивиденти

By Dow Jones

Следващи печалби

6.08.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

26M

282M

Предишно отваряне

-0.38

Предишно затваряне

1.25

Настроения в новините

By Acuity

50%

50%

154 / 376 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

Allogene Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

18.07.2025 г., 21:01 ч. UTC

Печалби

Charles Schwab Profit Jumps on Tariff Trading Surge -- 2nd Update

18.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

18.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

18.07.2025 г., 20:50 ч. UTC

Пазарно говорене
Печалби

Basic Materials Roundup: Market Talk

18.07.2025 г., 20:46 ч. UTC

Печалби

Strong Earnings Fuel Stock-Market Records This Week -- WSJ

18.07.2025 г., 20:39 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18.07.2025 г., 20:36 ч. UTC

Печалби

3M Gives Investors a 'Beat and Raise.' The Stock Is Rising. -- Barrons.com

18.07.2025 г., 20:16 ч. UTC

Придобивния, сливания и поглъщания

Chevron-Hess Deal Close Is Good News for Wall Street's Takeover Arbitragers -- Barrons.com

18.07.2025 г., 20:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

18.07.2025 г., 20:02 ч. UTC

Пазарно говорене

Gold Higher to Close Out Week -- Market Talk

18.07.2025 г., 19:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Weekly Gains -- Market Talk

18.07.2025 г., 19:06 ч. UTC

Пазарно говорене

Oil Futures Snap Two-Week Winning Streak -- Market Talk

18.07.2025 г., 18:24 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Netflix, Sarepta, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, and More -- Barrons.com

18.07.2025 г., 18:19 ч. UTC

Печалби

American Express Shares Drop as Earnings Beat, Record Revenue Fail to Impress -- Barrons.com

18.07.2025 г., 18:11 ч. UTC

Придобивния, сливания и поглъщания

Oil CEOs Get Their Revenge on Biden's Antitrust Enforcers -- WSJ

18.07.2025 г., 18:11 ч. UTC

Печалби

Netflix Earnings Show That YouTube Is the Streamer to Fear -- Barrons.com

18.07.2025 г., 17:35 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Falls by 2 to 422 -- Market Talk

18.07.2025 г., 16:29 ч. UTC

Пазарно говорене

Crude Rally on EU's Russia Sanctions Peters Out -- Market Talk

18.07.2025 г., 16:28 ч. UTC

Придобивния, сливания и поглъщания

Union Pacific Considering a Norfolk Southern Buyout, Report Says. Here's What Will Matter. -- Barrons.com

18.07.2025 г., 16:22 ч. UTC

Печалби

These Stocks Are Moving the Most Today: Netflix, Amex, Norfolk Southern, Interactive Brokers, Talen, Schwab, Sarepta, and More -- Barrons.com

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Financial Services Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Tech, Media & Telecom Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Auto & Transport Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

18.07.2025 г., 16:20 ч. UTC

Пазарно говорене
Печалби

Basic Materials Roundup: Market Talk

18.07.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

18.07.2025 г., 16:04 ч. UTC

Печалби

Charles Schwab Profit Jumps on Tariff Trading Surge -- Update

18.07.2025 г., 15:58 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

18.07.2025 г., 15:58 ч. UTC

Пазарно говорене

Aluminum Gains on U.S. Dollar Weakness, Scrap Imports -- Market Talk

18.07.2025 г., 15:47 ч. UTC

Пазарно говорене
Печалби

Netflix Shifting Focus to Engagement with New Content -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Allogene Therapeutics Inc Прогноза

Ценова цел

By TipRanks

593.6% нагоре

12-месечна прогноза

Среден 8.67 USD  593.6%

Висок 14 USD

Нисък 4 USD

Според 13 анализатори от Wall Street, предложили 12-месечна ценова цел за Allogene Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

13 ratings

11

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

1.18 / 1.69Подкрепа & съпротива

Краткосрочен план

Very Strong Bearish Evidence

Средносрочен план

Weak Bullish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

154 / 376 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.